T1-Weighted Intensity Increase After a Single Administration of a Linear Gadolinium-Based Contrast Agent in Multiple Sclerosis

Sophia Grahl, Matthias Bussas, Viola Pongratz, Jan S. Kirschke, Claus Zimmer, Achim Berthele, Bernhard Hemmer, Mark MühlauClinical 2020 · DOI

Abstract: The data point towards Gd deposition in the brain after administration of linear GBCA even after a single administration.

Introduction

Gadolinium-based contrast agents (GBCAs) are indispensable in neuroradiology, particularly for the longitudinal monitoring of Multiple Sclerosis (MS). While these agents were long considered safe, recent evidence suggests that gadolinium (Gd) can deposit and persist in brain tissue—specifically within the dentate nucleus and globus pallidus—following repeated administrations.

GBCAs are broadly categorized into two structural classes: linear and cyclic. Linear agents, where the organic ligand "wraps" around the Gd ion, are known to be less thermodynamically stable than cyclic agents, which "cage" the ion more securely. This study investigates a critical question: does deposition require a high cumulative dose, or does it begin after the very first injection? Furthermore, the study examines whether this deposition is reversible over time.

Methodology

The researchers performed a retrospective analysis of 3,233 T1-weighted (T1w) MRI scans from 881 MS patients collected between 2009 and 2017. To isolate the effects of individual contrast administrations, the team employed a "difference image" approach.

Timeline of GBCA administration and MRI scan intervals used to isolate the effects of specific agent types.

Key steps in the image processing pipeline included:

  1. Spatial Normalization: Mapping all scans to a standard MNI brain template.
  2. Intensity Scaling: Using the pons as an internal reference structure to account for inter-scanner variability.
  3. Ratio Calculation: Focusing on the Dentate Nucleus-to-Pons (DN/P) intensity ratio.
  4. Delta Analysis: Calculating the difference in signal between subsequent scans and attributing that change to the specific agent (Linear, Cyclic, or No GBCA) administered during the first scan of the pair.

The linear agent studied was gadopentetic acid (Magnevist), while the cyclic agent was gadoterate meglumine (Dotarem).

Results

The Single-Dose Threshold

The most significant finding is that the detection threshold for Gd deposition is lower than previously hypothesized. For linear agents, a single dose was sufficient to cause a statistically significant increase in T1 signal intensity ($p < 0.001$). This increase was largely independent of the patient's prior cumulative dose, suggesting a linear relationship where each administration adds a consistent layer of deposition.

Axial T1-weighted MRI showing hyperintensity in the dentate nucleus (red arrows) following linear GBCA administration.

Stability and Regional Specificity

The study reinforced the superior safety profile of cyclic agents. Even in this frequently scanned MS cohort, cyclic GBCAs did not result in measurable T1 signal increases. Voxel-wise analysis confirmed that for linear agents, signal increases were localized specifically to the dentate nucleus and the globus pallidus.

Persistence of Signal

The researchers found no evidence of "washout" or reversibility. Signal intensity did not decline over time following deposition, suggesting that once linear Gd deposits in these brain regions, it remains there long-term. Additionally, a small but significant correlation ($R^2 = 0.01, p = 0.005$) was found between disability scores (EDSS) and the frequency of GBCA administrations, likely reflecting the more frequent monitoring required for severely affected patients.

Discussion and Conclusion

This study demonstrates that gadolinium deposition from linear agents is an immediate process rather than a late-stage cumulative effect. While the study confirms that deposition occurs, it does not establish whether this retention leads to clinical toxicity.

Limitations include the retrospective nature of the data and the use of T1w signal intensity as a proxy for Gd concentration rather than direct molar measurement. Future research must address the long-term biological consequences of retained gadolinium and investigate whether different MS phenotypes exhibit varying accumulation kinetics. For now, the data strongly supports the use of cyclic GBCAs to minimize the risk of intracranial metal deposition.

Summary updated

Abstract

The data point towards Gd deposition in the brain after administration of linear GBCA even after a single administration.
BibTeX
@inproceedings{grahl2020t,
  author = {Sophia Grahl and Matthias Bussas and Viola Pongratz and Jan S. Kirschke and Claus Zimmer and Achim Berthele and Bernhard Hemmer and Mark Mühlau},
  title = {{T1-Weighted Intensity Increase After a Single Administration of a Linear Gadolinium-Based Contrast Agent in Multiple Sclerosis}},
  booktitle = {Clinical},
  year = {2020},
  doi = {10.1007/s00062-020-00882-6},
}
Figure